{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:55:16Z","timestamp":1791428116163,"version":"4.3.3"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"\n Importance<\/jats:title>\n The role of preoperative radiotherapy after neoadjuvant chemotherapy for pancreatic cancer remains controversial.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate whether the addition of radiotherapy to chemotherapy is associated with improved oncologic outcomes in patients undergoing resection for pancreatic cancer.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a retrospective propensity score\u2013matched cohort study of patients undergoing pancreatic cancer resection between 2015 and 2023, with a median follow-up of 44 months. Patients were recruited from 2 high-volume referral centers. Of patients undergoing pancreatectomy after neoadjuvant treatment for pancreatic ductal adenocarcinoma, those treated with fluorouracil, leucovorin, irinotecan, and oxaliplatin or gemcitabine\/nab-paclitaxel with or without preoperative radiation met eligibility criteria. Patients with metastatic disease, surgery-related mortality, or follow-up less than 12 months were excluded. Treatment groups were matched 1:1 on age, sex, comorbidity, tumor characteristics, baseline carbohydrate antigen 19-9 level, resectability status, and chemotherapy exposure.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Neoadjuvant chemotherapy with or without radiotherapy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Event-free survival, pattern of recurrence, and overall survival.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 1201 consecutive patients undergoing pancreatectomy after neoadjuvant treatment for pancreatic ductal adenocarcinoma, 869 met eligibility criteria. Among 800 included patients (median [IQR] age, 65 [58-71] years; 402 men [50.2%]), 438 received neoadjuvant chemotherapy and radiotherapy and 362 chemotherapy alone. After matching, 226 patients per group were analyzed; most had resectable (117 of 226 [51.1%]) or borderline-resectable (104 of 226 [46.5%]) disease. Radiotherapy was associated with higher rates of pathologic complete response (15 of 226 [6.6%] vs 10 of 226 [4.4%]), node-negative disease (139 of 226 [61.5%] vs 76 of 226 [33.6%]), and R0 resection (192 of 226 [85.0%] vs 118 of 226 [52.2%]). Recurrence patterns were similar, with distant recurrence as the predominant first site of failure in both groups (116 of 226 [51.3%] vs 109 of 226 [48.3%]). In competing risk analysis, the cumulative incidence of locoregional recurrence did not differ (subdistribution hazard ratio [HR], 0.90; 95% CI, 0.53-1.54;\n P<\/jats:italic>\n \u2009=\u2009.71). Radiotherapy was not associated with improved event-free survival (HR, 1.10; 95% CI, 0.88-1.37;\n P<\/jats:italic>\n \u2009=\u2009.38) or overall survival (HR, 1.02; 95% CI, 0.79-1.32;\n P<\/jats:italic>\n \u2009=\u2009.84).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Results of this cohort study suggest that although the addition of radiotherapy to neoadjuvant chemotherapy was associated with an improved pathologic response, it was not associated with survival benefit or reduced recurrence in resectable and borderline-resectable pancreatic cancer. These findings highlight the limited impact of locoregional control in a disease driven by systemic progression.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamasurg.2026.3716","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:30:47Z","timestamp":1787758247000},"page":"1043","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1001","volume":"161","author":[{"given":"Federico","family":"De Stefano","sequence":"first","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Pancreatic and Transplant Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel F.","family":"Wu","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Belfiori","sequence":"additional","affiliation":[{"name":"Division of Pancreatic and Transplant Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah J.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ferrone","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Aleotti","sequence":"additional","affiliation":[{"name":"Division of Pancreatic and Transplant Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill N.","family":"Allen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Balzano","sequence":"additional","affiliation":[{"name":"Division of Pancreatic and Transplant Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Blaszkowsky","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Clark","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Cobelli","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, Milan, Italy"},{"name":"Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Fagenholz","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gasparini","sequence":"additional","affiliation":[{"name":"Division of Pancreatic and Transplant Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon M.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, Milan, Italy"},{"name":"Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadarshini S.","family":"Pathak","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Pecorelli","sequence":"additional","affiliation":[{"name":"Division of Pancreatic and Transplant Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Schiavo","family":"Lena","sequence":"additional","affiliation":[{"name":"Department of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Tamburrino","sequence":"additional","affiliation":[{"name":"Division of Pancreatic and Transplant Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin D.","family":"Weekes","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motaz","family":"Qadan","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Partelli","sequence":"additional","affiliation":[{"name":"Division of Pancreatic and Transplant Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Lillemoe","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y.","family":"Wo","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Crippa","sequence":"additional","affiliation":[{"name":"Division of Pancreatic and Transplant Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[{"name":"Division of Pancreatic and Transplant Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fern\u00e1ndez-del Castillo","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"soi260054r1","first-page":"10","article-title":"Cancer statistics, 2025.","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"soi260054r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040.","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"soi260054r3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.annonc.2025.01.014","article-title":"European cancer mortality predictions for the year 2025 with focus on breast cancer.","volume":"36","author":"Santucci","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"soi260054r4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","article-title":"Neoadjuvant therapy for pancreatic cancer.","volume":"20","author":"Springfeld","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"soi260054r5","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1097\/SLA.0000000000006269","article-title":"Trends over time in recurrence patterns and survival outcomes after neoadjuvant therapy and surgery for pancreatic cancer.","volume":"282","author":"Cass","year":"2025","journal-title":"Ann Surg"},{"issue":"1","key":"soi260054r6","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-26-515560","article-title":"Contemporary multidisciplinary treatment of borderline-resectable and locally advanced pancreatic adenocarcinoma.","volume":"46","author":"Joung","year":"2026","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10522","key":"soi260054r7","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1016\/S0140-6736(25)01685-X","article-title":"Preoperative mFOLFIRINOX vs PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomization analysis of a randomized, open-label, 2?\u00d7?2 factorial phase 3 trial.","volume":"406","author":"Reni","year":"2026","journal-title":"Lancet"},{"issue":"11","key":"soi260054r8","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy vs upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial.","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"soi260054r9","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.ccell.2025.09.009","article-title":"Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: a randomized phase 3 trial.","volume":"43","author":"Bai","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"soi260054r10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/SLA.0000000000006730","article-title":"Neoadjuvant chemotherapy with gemcitabine and S-1 vs upfront surgery for resectable pancreatic cancer: results of the randomized phase II\/III Prep-02\/JSAP05 trial.","volume":"283","author":"Unno","year":"2026","journal-title":"Ann Surg"},{"issue":"6","key":"soi260054r11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","article-title":"Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomized, open-label, phase 2-3 trial.","volume":"3","author":"Reni","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"soi260054r12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","article-title":"Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX): a randomized phase II trial of the AIO pancreatic cancer group.","volume":"34","author":"Seufferlein","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"soi260054r13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial.","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"},{"issue":"16","key":"soi260054r14","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2022.40.16_suppl.4134","article-title":"Resectable pancreatic adenocarcinoma neoadjuvant FOLF(IRIN)OX-based chemotherapy: a multicenter, noncomparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).","volume":"40","author":"Schwarz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"soi260054r15","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1200\/JCO.22.01134","article-title":"Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase iii trial.","volume":"41","author":"Tempero","year":"2023","journal-title":"J Clin Oncol"},{"issue":"25","key":"soi260054r16","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"soi260054r17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/bjs\/znac002","article-title":"Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis.","volume":"109","author":"Oba","year":"2022","journal-title":"Br J Surg"},{"issue":"34","key":"soi260054r18","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.21.01220","article-title":"Value of neoadjuvant radiation therapy in the management of pancreatic adenocarcinoma.","volume":"39","author":"Hall","year":"2021","journal-title":"J Clin Oncol"},{"issue":"30","key":"soi260054r19","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO-24-01502","article-title":"Benefit of chemoradiotherapy vs chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: the randomized CONKO-007 trial.","volume":"43","author":"Fietkau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"17","key":"soi260054r20","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial.","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"soi260054r21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a 4-arm, multicenter, randomized, phase 2 trial.","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"soi260054r22","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","article-title":"Neoadjuvant FOLFIRINOX vs neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomized trial.","volume":"26","author":"Janssen","year":"2025","journal-title":"Lancet Oncol"},{"key":"soi260054r23","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17988-1","article-title":"Comparison between neoadjuvant chemoradiotherapy and chemotherapy for patients with resectable pancreatic cancer.","author":"Murakami","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"soi260054r24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.6004\/jnccn.2022.7008","article-title":"Neoadjuvant radiotherapy after (m)FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: a TAPS Consortium study.","volume":"20","author":"Janssen","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"soi260054r26","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"soi260054r27","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3390\/cancers12061681","article-title":"Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM).","volume":"12","author":"Silvestris","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"soi260054r28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw323","article-title":"Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies.","volume":"109","author":"Yao","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"soi260054r29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"3","key":"soi260054r30","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zraf033","article-title":"Anatomically resectable vs biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological aggressiveness.","volume":"9","author":"Belfiori","year":"2025","journal-title":"BJS Open"},{"issue":"1","key":"soi260054r31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"issue":"2","key":"soi260054r32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: 5-year experience.","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"issue":"4","key":"soi260054r33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1245\/s10434-017-6025-x","article-title":"8th Edition of the AJCC Cancer Staging Manual: pancreas and hepatobiliary cancers.","volume":"25","author":"Chun","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"soi260054r34","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1477-2574.2009.00055.x","article-title":"Redefining resection margin status in pancreatic cancer.","volume":"11","author":"Verbeke","year":"2009","journal-title":"HPB (Oxford)"},{"issue":"9","key":"soi260054r35","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial.","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"soi260054r36","doi-asserted-by":"publisher","first-page":"S1252","DOI":"10.1016\/j.annonc.2024.08.2304","article-title":"LBA62 Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS\/PRODIGE 44.","volume":"35","author":"Lambert","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"soi260054r37","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1186\/s12885-023-11141-5","article-title":"Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial.","volume":"23","author":"van Dam","year":"2023","journal-title":"BMC Cancer"},{"issue":"16","key":"soi260054r38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4204","article-title":"Alliance A021806: a phase III trial evaluating perioperative vs adjuvant therapy for resectable pancreatic cancer.","volume":"41","author":"Chawla","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"soi260054r39","doi-asserted-by":"publisher","first-page":"8297","DOI":"10.1245\/s10434-021-10276-8","article-title":"Added value of radiotherapy following neoadjuvant FOLFIRINOX for resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis.","volume":"28","author":"Janssen","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"soi260054r40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1245\/s10434-018-6931-6","article-title":"How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma: an AGEO-FRENCH multicentric cohort.","volume":"26","author":"Pietrasz","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"soi260054r41","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/JS9.0000000000000792","article-title":"Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis.","volume":"110","author":"Leonhardt","year":"2024","journal-title":"Int J Surg"},{"issue":"3","key":"soi260054r42","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/jso.26510","article-title":"Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma.","volume":"124","author":"Narayanan","year":"2021","journal-title":"J Surg Oncol"},{"issue":"1","key":"soi260054r43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41416-025-03025-1","article-title":"Survival after neoadjuvant and induction FOLFIRINOX vs gemcitabine-nab-paclitaxel in patients with resected localized pancreatic adenocarcinoma: an international multicenter study.","volume":"133","author":"Stoop","year":"2025","journal-title":"Br J Cancer"},{"issue":"6","key":"soi260054r44","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1245\/s10434-026-19218-8","article-title":"Risk factors for early disease-related mortality among patients with localized pancreatic cancer resected after neoadjuvant treatment.","volume":"33","author":"De Stefano","year":"2026","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"soi260054r45","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1245\/s10434-024-15105-2","article-title":"Very early recurrence after curative resection for pancreatic ductal adenocarcinoma: proof of concept for a \u201cbiological R2 definition\u201d.","volume":"31","author":"Belfiori","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"soi260054r46","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.surg.2021.10.015","article-title":"Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy.","volume":"171","author":"Maeda","year":"2022","journal-title":"Surgery"},{"issue":"5","key":"soi260054r47","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.surg.2024.07.026","article-title":"Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence.","volume":"176","author":"Tamburrino","year":"2024","journal-title":"Surgery"},{"issue":"3","key":"soi260054r48","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/SLA.0000000000001850","article-title":"Locally advanced pancreatic cancer: neoadjuvant therapy with FOLFIRINOX results in resectability in 60% of the patients.","volume":"264","author":"Hackert","year":"2016","journal-title":"Ann Surg"},{"issue":"5","key":"soi260054r49","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/SLA.0000000000005120","article-title":"Survival benefit associated with resection of locally advanced pancreatic cancer after upfront FOLFIRINOX vs FOLFIRINOX only: multicenter propensity score-matched analysis.","volume":"274","author":"Brada","year":"2021","journal-title":"Ann Surg"},{"key":"soi260054r25","unstructured":"National Comprehensive Cancer Network. Welcome to NCCN.org home page. Accessed July 23, 2026. https:\/\/www.nccn.org"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2853286\/jamasurgery_de_stefano_2026_oi_260054_1791304716.34508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:01:13Z","timestamp":1791385273000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2853286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2026.3716","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}